Phase 3
N=65
In Situ Caries Model of Fluoride Toothpastes
Caries
Bottom Line
View on ClinicalTrials.gov: NCT01005966 ↗Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Jul 2013
Primary outcome: Primary: Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF) — 38.05; 41.06 Percentage SMHR — p=0.2117
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Sodium Fluoride Toothpaste (Drug); Amine Fluoride Toothpaste (Drug); Sodium monofluorophosphate/Sodium Fluoride Toothpaste (Drug); Placebo (Drug); 675 ppmf toothpaste (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Mar 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF) |
38.05; 41.06 | 0.2117 |
| SECONDARY Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF) |
38.05; 41.06; 33.48; 29.08; 14.49 | 0.0002 sig |
| SECONDARY Change From Baseline in Enamel Fluoride Uptake Potential |
2342.35; 2305.11; 1809.74; 1649.44; 462.95 | 0.7912 |
Summary
This study is to evaluate the effect of fluoride dentrifrices on enamel with artificial caries lesions in an in situ model
Eligibility Criteria
Inclusion Criteria
- Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
- Age:Aged 18 to 80 years inclusive
- Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions
- General Health: Good general health with (in the opinion of the investigator) no clinically significant and/or relevant abnormalities of medical history or oral examination that could interfere with subject safety during the study period
- Residency: Currently living in the Indianapolis, Indiana area
- Dentures: a) Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 x 7 millimeters (mm). b) Willing and capable of wearing their removable partial dentures 24 hours per day during each two week treatment period. c) All restorations in a good state of repair
- Salivary Flow: Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/minute; gum base stimulated whole saliva flow rate ≥ 0.8 mL/minute).
Exclusion Criteria
- Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study
- Breast-feeding: Women who are breast-feeding
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
- Clinical Study/Experimental Medication: a. Participation in another clinical study or receipt of an investigational drug within 30 days of the first treatment visit, with the exception of study GSK dental studies where the wash in period prior to treatment is sufficient. b. Previous participation in this study
- Antibiotics: Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit
- Fluoride: Prescribed or professionally recommended use of fluoride supplements or fluoride mouthrinse
- Substance abuse: Recent history (within last year) of alcohol or other substance abuse
- Dental Health: Current active caries or periodontal disease that may compromise the study or health of the subjects
- Personnel: a. A member of the site study staff who is directly working on the project or living in that staff's household. b. An employee of the sponsor c. Any employee of any toothpaste manufacturer or their spouse or family member
Data sourced from ClinicalTrials.gov (NCT01005966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.